TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Local Anesthetic Wound Infusion and Functional Recovery After Colon Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing elective open colon surgery~Exclusion Criteria:~* ASA physical status 4~* history of:~  * hepatic failure (liver enzymes abnormally elevated)~ * renal failure (creatinine over 150 mmol/L)~ * cardiac failure~ * organ transplant~ * diabetes~ * morbid obesity (BMI \> 40 kg/m-2)~ * chronic use of opioids~ * allergy to local anaesthetics~* History of seizure~* contraindications to the insertion of epidural~* INR \> 1.3, PTT \> 44 second, platelets \< 150.000 per microliter,~* previous spinal surgery limiting the insertion)~* inability to comprehend pain assessment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Epidural analgesia group (Type: EXPERIMENTAL): patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
- Wound Group (Type: EXPERIMENTAL): patients in the epidural analgesia group will receive ropivacaine 0.2% through the wound catheter, normal saline in the epidural catheter and PCA with morphine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Hospitalized patient~2. Age \>= 18 years~3. Able to ingest oral medication or be administered medication via gastric tube or equivalent~4. Laboratory confirmation of SARS-CoV-2 infection within 1 week prior to randomization~5. Randomization within 72 hr of hospital admission~6. Negative pregnancy test for reproductive age women~7. Patient or LAR able to provide informed consent~Exclusion criteria~1. Allergy or intolerance to losartan or other ARBs~2. Already taking ACE or ARB (within 1 month)~3. Hypotension at time of enrollment (SBP \< 100 mm Hg)~4. Hyperkalemia (K \>/= 5.0 at time of screening or history of hyperkalemia)~5. Severe renal dysfunction (estimated GFR \< 30 ml/min at time of screening or history advanced renal disease)~6. Severe volume depletion or acute kidney injury (AKI) at time of enrollment~7. Known cirrhotic ascites~8. Known severe aortic or mitral valve stenosis~9. Known unstented renal artery stenosis~10. Co-administration with certain drugs due to CYP3A interactions if taken in \< 24 hr~11. Severe hepatic insufficiency (LFTs \> 5 times the upper limit of normal or known ESLD or cirrhosis)~12. Nausea/vomiting or aspiration risk precluding oral medications unless can be given by gastric tube~13. Pregnancy or breast feeding~14. Absence of dependable contraception in reproductive age women~15. Inability to obtain or declined informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Losartan (Type: EXPERIMENTAL): losartan 25 mg po QD X 14 days
- Placebo (Type: PLACEBO_COMPARATOR): placebo QD X 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Preeclampsia With Aspirin in Recipients of Donated Oocytes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years.~* Recipients of donated oocytes.~* Pregnant women.~* Single or twin gestations.~* Patients who accept the conditions of the study by signing the appropriate informed consent.~Exclusion Criteria:~* Known allergy to acetylsalicylic acid .~* Personal history of peptic ulcer.~* Triplets.~* Use of prostaglandin inhibitors within 10 days prior to baseline.~* Personal history of chronic kidney, thyroid, liver or heart disease.~* Psychiatric or cognitive pathology that prevents understanding of the conditions of informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- acetylsalicylic acid (Type: EXPERIMENTAL): This group will receive 1 tablet of acetylsalicylic acid (100 mg) orally daily from 5-10 weeks gestation until the end of gestation, about week 36
- Placebo (Type: PLACEBO_COMPARATOR): This group will receive 1 tablet of placebo orally each day from 5-10 weeks gestation until the end of gestation, about week 36

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients \> 18 years of age.~* Detectable plasma HCV-RNA by qualitative PCR assay.~* HCV genotype 1 infection,~* Documented recurrent hepatitis C by liver biopsy within the past year.~* On cyclosporine or tacrolimus-based immunosuppression~* Negative urine pregnancy test before initiating the treatment for women of childbearing potential.~* Willingness of the patient and all potentially childbearing partners to use a reliable form of effective contraception during the study, unless the patient or partner is surgically sterile or post-menopausal.~* Willingness to undergo provide informed consent and comply with study requirements.~Exclusion Criteria:~* Genotype non-1 HCV infection.~* Women who are pregnant or breast-feeding.~* Male partners of women who are pregnant.~* Evidence of co-infection with HIV or hepatitis B.~* History of severe psychiatric disease.~* History of immunologically mediated disease (e.g., inflammatory bowel disease, lupus erythematosus, rheumatoid arthritis, etc.)~* History of clinically significant pulmonary disease.~* History of severe cardiac disease.~* History of malignancy where risk of recurrence is \>20% within 2 years.~* History of uncontrolled seizure disorder.~* History of poorly controlled thyroid disease.~* History of poorly controlled diabetes mellitus.~* History of severe retinopathy.~* Active gout.~* History or evidence of severe medical illness that, in the opinion of the investigator, makes the patient unsuitable for pegylated interferon alfa-2a treatment (Pegasys®).~* Inability or unwillingness to abstain from alcohol throughout the entire study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HCV, LT, Pegasys, ribavirin, telaprevir (Type: EXPERIMENTAL): Patients are being asked to be part of this arm because they are orthotopic liver transplant recipients (OLT) and have the Hepatitis C Virus (HCV). They will be given the study drugs Pegasys, ribavirin and telaprevir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC) with progressive disease after at least one platinum-based chemotherapeutic regimen and with evaluable or measurable disease~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Adequate hematologic, hepatic, and renal function~Exclusion Criteria:~* Has active, known, or suspected autoimmune disease~* Had prior exposure to an immuno-oncology or pyrrolobenzodiazepine (PBD)-based drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rovalpituzumab Tesirine and Nivolumab (Type: EXPERIMENTAL): Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine by intravenous (IV) infusion 6 weeks apart (Day 1 of Cycles 1 and 3), and 2 doses of 360 mg nivolumab IV 3 weeks apart beginning on Cycle 2 (Day 1 of Cycles 2 and 3).~Participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 4 until disease progression.
- Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 1 mg/kg (Type: EXPERIMENTAL): Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 1 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After a 6-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression.
- Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 3 mg/kg (Type: EXPERIMENTAL): Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 3 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After an 8-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of Mixed Venous Blood Oxygen Saturation Obtained With a Novel Mathematical Equation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients already being monitored by a pulmonary artery catheter and an arterial line~Exclusion Criteria:~* Patients with severe heart failure~* Patients with carbon monoxide or thiocyanate poisoning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Mixed venous oxygen saturation measurement obtained from blood drawn from a pulmonary artery catheter.Calculation of mixed venous oxygen saturation from the measurement of peripheral oxygen saturations using multiple Cerebral/Somatic Tissue Oximeter device probes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Avelle® Negative Pressure Wound Therapy System on Chronic Wounds

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Venous insufficiency as defined by CEAP Classification of C6 or C6R or Diabetic foot ulcer~* Stalled wound/failed treatment in the opinion of the investigator. Defined as a wound that has not progressed by more than 30% in the previous 4 weeks~* 1 qualifying wound which is amenable to NPWT~* Reliable and available for follow-up~* Low to moderate exudate~* Able to tolerate negative pressure~* \>18 years old at the time of consent~* Able and willing to provide informed consent~Exclusion Criteria:~* Known sensitivities or allergies to components of the Avelle™ Negative Pressure Wound Therapy System~* Necrotic wounds or wounds with eschar present~* Wound is too small or too large based on wound dressing (\> 1cm2 and \< 100cm2)~* Wound depth \>2cm~* Use of DuoDERM® gel /petroleum gel/ creams/oil-based products~* Active treatment for cancer or completed within the last 3 months~* Severe malnutrition in the opinion of the investigator~* Visible bone/tendon or exposed articular capsule~* Exposed blood vessels~* Clotting disorder~* Malignant wounds~* Systemic infection~* Untreated osteomyelitis~* Patients with HbA1c greater than 9 on Day 0 (Test to be performed within last 3 months)~* Wounds greater than 12 months old~* Previous failed NPWT within last 6 weeks on the qualifying wound~* Active Pregnancy~* Chronic Kidney Disease score of 5

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avelle NPWT (Type: None): Avelle Negative Pressure Wound Therapy administered as indicated by the IFU.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Trial Comparing Oxycodone Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Be at least 18 years old.~2. Be able to read and understand English.~3. Have a diagnosed chronic pain condition with pain every day or most days for the previous 6 months.~4. Be receiving the equivalent of no more than 40-120 mg daily of an opioid analgesic that can be safely converted to oxycodone; this dosage includes all use of opioid analgesics, including for rescue and for breakthrough pain.~5. Have an average daily pain rating for the baseline week of pain ratings equal to 4.0 or greater on a 0-10 numerical pain rating scale (NRS) of average pain intensity in the past 24 hours.~6. Have completed at least 6 of the 7 daily diaries during the baseline week.~7. Have at least 5 baseline week pain diary ratings equal to 3 or greater on the 0-10 NRS, with no more than one rating of 9 and no ratings of 10.~8. Have stable concomitant use of all pain-related medications for 8 weeks prior to screening and being willing to continue stable use of these medications for the duration of the trial.~9. Have the ability to either independently or with an accompanying person come to the research center for study visits.~Exclusion Criteria:~1. Treatment of their chronic pain with nerve blocks or any other interventional procedure within the past 8 weeks.~2. A Beck Depression Inventory score \< 27 at baseline or clinically significant depression or dementia that, in the opinion of the investigator, may interfere with a subjects' adherence to the study protocol and/or the accurate and consistent reporting of pain.~3. History of suicide attempt within the past 2 years or current suicide plan or intent.~4. History of excessive alcohol use or any illicit drug use within the past 2 years.~5. Lack of adequate birth control in pre-menopausal women of child-bearing age and/or a positive urine pregnancy test, which will be performed on all women except those \> 2 years post-menopausal or who have had a hysterectomy).~6. History of malignancy within the past five years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinomas of the skin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ER Oxycodone vs IR Oxycodone (Type: ACTIVE_COMPARATOR): Extended release Oxycodone to assess pain relief adverse effects, treatment satisfaction and impact of treatment on health related quality of life.~IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every four hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have the diagnosis of hypothyroidism.~* Patients must be already on thyroid hormone replacement.~* Patients must be greater than or equal to 18 years old.~* Patients must have a diagnosis of a primary or secondary brain tumor and must have received prior radiation.~* Patients must have a life expectancy of at least 6 months.~Exclusion Criteria:~* Previously established dementing illness.~* Other medical conditions known to cause dementia.~* Significant psychiatric illness.~* Uncontrolled seizures.~* Acute or chronic pulmonary disease.~* Active severe infections.~* Signs or symptoms of coronary artery disease.~* History of congenital hypothyroidism, hyperthyroidism, thyroidectomy, 131I-therapy, or thyroid cancer.~* Paroxysmal supraventricular tachycardia, or any serious unstable medical condition.~* Inability to read and write in English.~* Patients must not be taking any medications that interfere with thyroid hormone metabolism (Beta-Adrenergic Blocking Agents, Antiarrhythmic drugs, Antipsychotic Agents, Tricyclic Antidepressants, Amiodarone, Iodine, Lithium, and Alpha-Interferon).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levothyroxine + Liothyronine (Type: EXPERIMENTAL): Levothyroxine 75 mcg by mouth (PO) Daily for 8 Weeks + Liothyronine 15 mcg PO Daily for 8 Weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ruptured saccular aneurysm confirmed by angiography and repaired by neurosurgical clipping or endovascular coiling~2. External ventricular drain in place~3. Subarachnoid hemorrhage on computed tomography (CT) scan of grade 2-4 on the modified Fisher scale~4. WFNS grade 2, 3, or 4~Exclusion Criteria:~1. Major complication during aneurysm repair such as, but not limited to, massive intraoperative hemorrhage, brain swelling, arterial occlusion or inability to secure the ruptured aneurysm~2. Angiographic vasospasm prior to randomization~3. Evidence of a cerebral infarction with neurological deficit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EG-1962 Group (Type: EXPERIMENTAL): * 1 dose of intraventricular EG-1962 (nimodipine microparticles) 600 mg~* Up to 21 days of placebo capsules/tablets
- Enteral Nimodipine Group (Type: ACTIVE_COMPARATOR): * 1 dose of intraventricular normal saline~* Up to 21 days of oral nimodipine capsules/tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be a participant from Study 104RA202 (NCT 00664716)~* Stable dose of Methotrexate for the duration of the study~Exclusion Criteria:~* Participants with a significant change in their medical history from their previous BG9924 study~* Any clinically significant infectious illness or serious local infection~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 2 (Type: EXPERIMENTAL): Drug: BG9924 - dose administered as per Biogen-Idec protocol
- Group 1 (Type: EXPERIMENTAL): Drug: BG9924 - dose administered as per Biogen-Idec protocol
- Group 3 (Type: EXPERIMENTAL): Drug: BG9924 - dose administered as per Biogen-Idec protocol
- Group 4 (Type: EXPERIMENTAL): Drug: BG9924 - dose administered as per Biogen-Idec protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~A participant must meet all of the following criteria to be eligible for participation in the study:~* Adult male or female.~* Participant has suspected PSVT as per the online prescreening assessment.~* Participant lives in a country in which the registry is being conducted.~* Participant has signed the informed consent form indicating he/she is able to complete the online registry data collection forms on his/her own.~Exclusion Criteria:~* Participant does not have an email address.~* Participant does not set up a user account.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient-reported PSVT. (Type: None): Participants who recorded a PSVT diagnosis.
- Suspected PSVT. (Type: None): Participants who do not record a PSVT diagnosis.
- Other subgroups. (Type: None): Subgroups also may be examined ( PSVT-episode characteristics, use of a self-management technique for PSVT at home (on their own) to return heart rate back to normal).The sample size, however, may limit the extent of any subgroup analyses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues